Current Oncology Reports最新文献_第6页

The Role of Cannabinoids in Advancing Cancer Treatment: Insights from Evidence-Based Medicine. 大麻素在促进癌症治疗中的作用：来自循证医学的启示。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-08-07 DOI: 10.1007/s11912-024-01589-4

Magdalena Skórzewska, Katarzyna Gęca

{"title":"The Role of Cannabinoids in Advancing Cancer Treatment: Insights from Evidence-Based Medicine.","authors":"Magdalena Skórzewska, Katarzyna Gęca","doi":"10.1007/s11912-024-01589-4","DOIUrl":"https://doi.org/10.1007/s11912-024-01589-4","url":null,"abstract":"Purpose of review: This document critically examines the role of cannabinoids in cancer care during an era marked by rapid advancements in oncology and changing perceptions on cannabis. It traces the historical context of cannabis in medicinal use, navigating its journey from widespread acceptance, subsequent criminalization, to its resurgence in modern therapeutic applications, particularly within the framework of Evidence-Based Medicine (EBM).Recent findings: Anchored in EBM principles, this study synthesizes current research from clinical trials, systematic reviews, and meta-analyses to evaluate the efficacy and safety of cannabinoids in oncology. The focus is on their palliative effects, considering the nuances of effectiveness, risk assessment, and challenges inherent in translating these findings into clinical guidelines. The study seeks to bridge the gap between scientific research and clinical practice, offering insights to inform future oncological therapies and symptom management strategies involving cannabinoids. The potential benefits and risks of cannabinoid use in cancer treatment are assessed to guide clinicians and researchers in developing comprehensive, evidence-based approaches to patient care.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141897030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Palliative Rehabilitation in Patients with Cancer: Definitions, Structures, Processes and Outcomes. 癌症患者的姑息康复：定义、结构、过程和结果。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-08-05 DOI: 10.1007/s11912-024-01585-8

Jegy M Tennison, Jack B Fu, David Hui

{"title":"Palliative Rehabilitation in Patients with Cancer: Definitions, Structures, Processes and Outcomes.","authors":"Jegy M Tennison, Jack B Fu, David Hui","doi":"10.1007/s11912-024-01585-8","DOIUrl":"10.1007/s11912-024-01585-8","url":null,"abstract":"Purpose of review: This review examines the literature on palliative rehabilitation for patients with advanced cancer, focusing on definitions, structures, processes, and outcomes.Recent findings: Palliative cancer rehabilitation targets comfort and functional improvement for patients with limited rehabilitation potential across various settings. The palliative cancer rehabilitation team, typically led by a physician, coordinates symptom management and referrals to rehabilitation and other allied healthcare professionals as needed. The outcomes of palliative cancer rehabilitation varied widely by goals, settings, and interventions. Studies in hospice settings generally reported improved symptom control; inpatient rehabilitation had mixed functional outcomes; and outpatient palliative rehabilitation may contribute to enhanced functional and symptom outcomes, especially among patients with higher baseline function. Palliative cancer rehabilitation emphasizes a collaborative approach that integrates palliative care with rehabilitation interventions, aiming to enhance quality of life and address diverse patient needs. Further research and standardization are necessary to realize its full potential.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Perioperative Blood Transfusions and Cancer Progression: A Narrative Review. 围手术期输血与癌症进展：叙述性综述。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-08-01 Epub Date: 2024-06-07 DOI: 10.1007/s11912-024-01552-3

Layal Abou Daher, Olivia Heppell, Ileana Lopez-Plaza, Carlos E Guerra-Londono

引用次数: 0

From Detection to Cure - Emerging Roles for Urinary Tumor DNA (utDNA) in Bladder Cancer. 从检测到治愈--尿液肿瘤 DNA (utDNA) 在膀胱癌中的新作用。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-08-01 Epub Date: 2024-06-05 DOI: 10.1007/s11912-024-01555-0

Joshua A Linscott, Hiroko Miyagi, Prithvi B Murthy, Sijie Yao, G Daniel Grass, Aram Vosoughi, Hongzhi Xu, Xuefeng Wang, Xiaoqing Yu, Alice Yu, Logan Zemp, Scott M Gilbert, Michael A Poch, Wade J Sexton, Philippe E Spiess, Roger Li

{"title":"From Detection to Cure - Emerging Roles for Urinary Tumor DNA (utDNA) in Bladder Cancer.","authors":"Joshua A Linscott, Hiroko Miyagi, Prithvi B Murthy, Sijie Yao, G Daniel Grass, Aram Vosoughi, Hongzhi Xu, Xuefeng Wang, Xiaoqing Yu, Alice Yu, Logan Zemp, Scott M Gilbert, Michael A Poch, Wade J Sexton, Philippe E Spiess, Roger Li","doi":"10.1007/s11912-024-01555-0","DOIUrl":"10.1007/s11912-024-01555-0","url":null,"abstract":"Purpose of review: This review sought to define the emerging roles of urinary tumor DNA (utDNA) for diagnosis, monitoring, and treatment of bladder cancer. Building from early landmark studies the focus is on recent studies, highlighting how utDNA could aid personalized care.Recent findings: Recent research underscores the potential for utDNA to be the premiere biomarker in bladder cancer due to the constant interface between urine and tumor. Many studies find utDNA to be more informative than other biomarkers in bladder cancer, especially in early stages of disease. Points of emphasis include superior sensitivity over traditional urine cytology, broad genomic and epigenetic insights, and the potential for non-invasive, real-time analysis of tumor biology. utDNA shows promise for improving all phases of bladder cancer care, paving the way for personalized treatment strategies. Building from current research, future comprehensive clinical trials will validate utDNA's clinical utility, potentially revolutionizing bladder cancer management.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141246934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multiple Options: How to Choose Therapy in Frontline Metastatic Melanoma. 多种选择：如何选择前线转移性黑色素瘤的治疗方法？

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-08-01 Epub Date: 2024-06-05 DOI: 10.1007/s11912-024-01547-0

Lucy Boyce Kennedy, April K S Salama

引用次数: 0

Screening and Testing for Homologous Recombination Repair Deficiency (HRD) in Breast Cancer: an Overview of the Current Global Landscape. 乳腺癌同源重组修复缺陷（HRD）的筛查和检测：全球现状概览。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-08-01 Epub Date: 2024-06-01 DOI: 10.1007/s11912-024-01560-3

Gordon R Daly, Sindhuja Naidoo, Mohammad Alabdulrahman, Jason McGrath, Gavin P Dowling, Maen M AlRawashdeh, Arnold D K Hill, Damir Varešlija, Leonie Young

{"title":"Screening and Testing for Homologous Recombination Repair Deficiency (HRD) in Breast Cancer: an Overview of the Current Global Landscape.","authors":"Gordon R Daly, Sindhuja Naidoo, Mohammad Alabdulrahman, Jason McGrath, Gavin P Dowling, Maen M AlRawashdeh, Arnold D K Hill, Damir Varešlija, Leonie Young","doi":"10.1007/s11912-024-01560-3","DOIUrl":"10.1007/s11912-024-01560-3","url":null,"abstract":"Purpose of review: Homologous recombination repair deficiency (HRD) increases breast cancer susceptibility and influences both prophylactic and active management of breast cancer. This review evaluates HRD testing and the therapeutic implications of HRD in a global context.Recent findings: Ongoing research efforts have highlighted the importance of HRD beyond BRCA1/2 as a potential therapeutic target in breast cancer. However, despite the improved affordability of next-generation sequencing (NGS) and the discovery of PARP inhibitors, economic and geographical barriers in access to HRD testing and breast cancer screening do not allow all patients to benefit from the personalized treatment approach they provide. Advancements in HRD testing modalities and targeted therapeutics enable tailored breast cancer management. However, inequalities in access to testing and optimized treatments are contributing to widening health disparities globally.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11300621/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141186237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevention of Post-Mastectomy Pain Syndrome: A Review of Recent Literature on Perioperative Interventions. 预防乳房切除术后疼痛综合征：关于围手术期干预措施的最新文献综述。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-08-01 Epub Date: 2024-05-30 DOI: 10.1007/s11912-024-01553-2

Rachel R Wu, Simon Katz, Jing Wang, Lisa V Doan

引用次数: 0

An Annual Symposium on Disparities in Milwaukee, WI, with a 2023 Focus on Older Adults with Cancer. 威斯康星州密尔沃基市差异问题年度研讨会，2023 年重点关注患癌症的老年人。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-08-01 Epub Date: 2024-05-27 DOI: 10.1007/s11912-024-01525-6

Sailaja Kamaraju, June McKoy, Grant R Williams, Nikesha Gilmore, Christina Minami, Kathryn Bylow, Helena Rajalingam, Chandler S Cortina, Angela Beckert, Melinda Stolley, Dan Bullock, Razelle Kurzrock, Aminah Jatoi

{"title":"An Annual Symposium on Disparities in Milwaukee, WI, with a 2023 Focus on Older Adults with Cancer.","authors":"Sailaja Kamaraju, June McKoy, Grant R Williams, Nikesha Gilmore, Christina Minami, Kathryn Bylow, Helena Rajalingam, Chandler S Cortina, Angela Beckert, Melinda Stolley, Dan Bullock, Razelle Kurzrock, Aminah Jatoi","doi":"10.1007/s11912-024-01525-6","DOIUrl":"10.1007/s11912-024-01525-6","url":null,"abstract":"Purpose of review: Cancer-related inequities are prevalent in Wisconsin, with lower survival rates for breast, colorectal, and lung cancer patients from marginalized communities. This manuscript describes the ongoing efforts at the Medical College of Wisconsin and potential pathways of community engagement to promote education and awareness in reducing inequities in cancer care.Recent findings: While some cancer inequities are related to aggressive disease biology, health-related social risks may be addressed through community-academic partnerships via an open dialogue between the community members and academic faculty. To develop potential pathways of community-academic partnerships, an annual Cancer Disparities Symposium concept evolved as a pragmatic and sustainable model in an interactive learning environment. In this manuscript, we describe the programmatic development and execution of the annual Cancer Disparities Symposium, followed by highlights from this year's meeting focused on geriatric oncology as discussed by the speakers.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11300154/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141154838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of Localized Melanoma in the Anti-PD-1 Era. 抗PD-1时代的局部黑色素瘤治疗。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-08-01 Epub Date: 2024-06-06 DOI: 10.1007/s11912-024-01556-z

Elan Novis, Alexander C J van Akkooi

{"title":"Management of Localized Melanoma in the Anti-PD-1 Era.","authors":"Elan Novis, Alexander C J van Akkooi","doi":"10.1007/s11912-024-01556-z","DOIUrl":"10.1007/s11912-024-01556-z","url":null,"abstract":"Purpose of review: The management of cutaneous melanoma has rapidly progressed over the past decade following the introduction of effective systemic therapies. Given the large number of recent clinical trials which have dramatically altered the management of these patients, an updated review of the current evidence regarding the management of localized melanoma is needed.Recent findings: The role of effective systemic therapies in earlier stages (I-III) melanoma, both in adjuvant and neoadjuvant settings is rapidly changing the role of surgery in the management cutaneous melanoma, particularly regarding surgical safety margins for wide local excision (WLE), the role of sentinel lymph node biopsy (SLNB) and the extent of lymph node dissections. The randomized phase 2 SWOG1801 trial has demonstrated superiority of neoadjuvant-adjuvant anti-PD1 therapy in improving event-free survival by 23% at 2-years over adjuvant anti-PD-1 therapy only. Furthermore, the PRADO trial has suggested a more tailored approach both the extent of surgery as well as adjuvant therapy can safely and effectively be done, depending on the response to initial neoadjuvant immunotherapy. These results await validation and it is expected that in 2024 the phase 3 Nadina trial (NCT04949113) will definitively establish neo-adjuvant combination immunotherapy as the novel standard. This will further redefine the management of localized melanoma. The use of effective systemic therapies will continue to evolve in the next decade and, together with new emerging diagnostic and surveillance techniques, will likely reduce the extent of routine surgery for stage I-III melanoma.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11300549/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141260475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Radiation and Melanoma: Where Are We Now? 辐射与黑色素瘤：我们现在在哪里？

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-08-01 Epub Date: 2024-06-01 DOI: 10.1007/s11912-024-01557-y

Roy Bliley, Adam Avant, Theresa M Medina, Ryan M Lanning

引用次数: 0